CD19靶向CAR-T细胞治疗14例复发难治性费城染色体阳性急性B前体淋巴细胞白血病的安全性与疗效
回顾性分析2016年11月至2019年4月接受CD19 CAR-T细胞治疗的14例复发难治性费城染色体阳性急性B前体淋巴细胞白血病患者,输注后第28天总反应率100.0%(14/14),完全缓解率92.9%(13/14);12例(85.7%)发生细胞因子释放综合征,不良反应均可控,中位总生存期515天、无进展生存期207天。
要点
- 14例R/R Ph(+) B-ALL患者CD19 CAR-T治疗后第28天ORR为100.0%(14/14),CR率92.9%(13/14)。
- 12例(85.7%)发生CRS,其中3级6例、4级1例;1例发生CRES;全部14例有Ⅲ~Ⅳ级血液学不良反应。
- 中位随访441天,中位OS为515天(95%CI 287~743),中位PFS为207天(95%CI 123~301)。
核心结论
- CD19 CAR-T细胞治疗复发难治性Ph(+) B-ALL安全有效,短期疗效显著,长期疗效有待进一步提高。
研究设计与样本
- 回顾性分析2016年11月至2019年4月采用CD19 CAR-T细胞治疗的14例R/R Ph(+) B-ALL患者的临床资料。
主要发现
- 14例患者中男7例、女7例,中位年龄33(7~66)岁。
- 输注后第28天ORR为100.0%(14/14),CR率为92.9%(13/14),PR率为7.1%(1/14)。
- 12例(85.7%)发生CRS:1级1例、2级4例、3级6例、4级1例;1例发生CRES;全部14例有Ⅲ~Ⅳ级血液学不良反应;13例CR患者均发生B细胞发育不全。
- 中位随访441(182~923)d,中位OS为515(95%CI 287~743)d,中位PFS为207(95%CI 123~301)d。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aimed to examine the safety and efficacy of CD19 chimeric antigen receptor T cell (CD19 CAR-T) therapy in relapsed/refractory Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia (R/R Ph(+) B-ALL) . Methods: The clinical data of 14 patients with R/R Ph(+) B-ALL treated with CD19 CAR-T cell therapy from November 2016 to April 2019 were retrospectively analyzed. Results: Among the 14 patients in this study, 7 were male and 7 were female, with a median age of 33 (7-66) years old. The efficacy was evaluated on the 28th day following CAR-T cells infusion; the overall response rate was 100.0% (14/14) , the complete response (CR) rate was 92.9% (13/14) , and the partial response (PR) rate was 7.1% (1/14) . After CAR-T cells infusion,12 cases (85.7%) developed cytokine release syndrome (CRS) : 1 case of grade 1 CRS, 4 cases of grade 2 CRS, 6 cases of grade 3 CRS, and 1 case of grade 4 CRS. Moreover, one case developed CAR T-cell-related encephalopathy syndrome (CRES) ; 14 cases had Ⅲ-Ⅳ hematological toxicity; and 13 CR cases had B cell dysplasia. These adverse reactions were all controllable. The median follow-up time was 441 (182-923) d. The median overall survival (OS) and progression-free survival (PFS) were 515 [95% confidence interval (CI) 287-743] days and 207 (95% CI 123-301) days, respectively. Conclusion: CD19 CAR-T cell therapy is safe and effective for R/R Ph(+) B-ALL treatment. However, the long-term efficacy needs to be further improved. 目的: 研究靶向CD19的嵌合抗原受体T细胞(CAR-T细胞)治疗复发难治Ph染色体阳性急性B淋巴细胞白血病(R/R Ph(+) B-ALL)的安全性及有效性。 方法: 对2016年11月至2019年4月采用CD19 CAR-T细胞治疗的14例R/R Ph(+) B-ALL患者的临床资料进行回顾性分析。 结果: 14例患者中,男7例,女7例,中位年龄33(7~66)岁。输注CAR-T细胞后第28天近期疗效:总反应率(ORR)为100.0%(14/14),其中完全缓解(CR)率为92.9%(13/14);部分缓解(PR)率为7.1%(1/14)。CAR-T细胞治疗后有12例(85.7%)发生细胞因子释放综合征(CRS),其中1级1例、2级4例、3级6例、4级1例;1例(例3)发生CAR-T细胞相关脑病综合征(CRES);全部14例患者均有Ⅲ~Ⅳ级血液学不良反应;13例CR患者均发生B细胞发育不全。上述不良反应均可控。中位随访441(182~923)d,中位总生存期、无进展生存期分别515(95% CI 287~743)d、207(95% CI 123~301)d。 结论: CD19 CAR-T细胞治疗复发难治性Ph(+) B-ALL安全有效,短期疗效显著,长期疗效有待进一步提高。.
引用
- He CX, Xue L, Qiang P, et al. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32654463. doi:10.3760/cma.j.issn.0253-2727.2020.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。